Navigation Links
Nanocells cancer combination therapy acts as chemotherapy as well as anti-angiogenic drug

Cancer chemotherapy is not effective in treating cancer efficiently due to its non-specificity and inability to target the cancer cells alone. Due to this non-specificity there is increased // development of drug resistance shown by these cancer cells.

Normal cells and cancer cells depend on blood supply for sustenance and oxygen. Cutting off blood supply could be one way to kill the cancer cells. This is however fraught with problems as cancer cells have a propensity to create new blood vessels. Anti-angiogenesis drug prevents formation of development of new blood vessels. This process of cutting off blood supply is called anti-angiogenesis.

Combining the two methods — chemotherapy and anti-angiogenesis — can be another way to kill cancer cells. This has it own limitations though — drugs that cut off blood supply not only deprive cancer cells of oxygen but also chemotherapy drugs that can kill the cancer cells.

`Nanocells' (of 200 nanometres in size) in a balloon within a balloon design — to deliver chemotherapy agents and drugs for destroying the blood supply to the cancer cells. The outer balloon has the anti-angiogenesis agent and the inner balloon has chemotherapy drugs.

"We tried the other combination but it will not work out," Dr. Sasisekharan explained. "First you need a vascular shut down (blood supply cut off) and then release the chemotherapy drug.”This will not only increase the therapeutic index but also decrease the toxicity. And this will happen only if the outer balloon is filled with an anti-angiogenesis drug."

The ability of the `nanocells' to wreak complete destruction of cancerous cells is aided by the cancerous cells themselves. "Tumour vessels suck things into their environment and the nanocells get trapped in the tumour bed due to their large size," he elucidated. The size of the nanocell plays a crucial role. While the 200 nanometre size of the nanocell prevents it from coming out of the blood vessel into organs, at the site of tumour it is a different story.

"Here the blood vessels are leaky and have pores as large as 400-600 nanometres," he noted. "So the nanocells can pass through the vessels into the tumour where they are retained." In other words Dr. Sasisekharan and his team used the difference in pathology of blood vessels in the tumour and the normal organs to selectively deliver the drugs.

Once inside the tumour, the nanocell's outer balloon disintegrates and the anti-angiogenesis drug brings about the blood vessel collapse, shrinkage and shut down. The chemotherapy drugs in the inner balloon are then released slowly as prolonged exposure of the tumour to chemotherapy has greater efficacy in killing cancer cells.

"It may not be optimal to release the anti-angiogenesis and chemotherapy drugs simultaneously as the chemotherapeutic drugs may leak out before the blood vessels inside the tumour are cut," he elucidated.

"If both drugs are released simultaneously, it becomes a simple combination therapy and though such a combination did show some efficacy (in our study), the nanocell was far superior to such a combination."

The team had worked on animal models to treat melanoma and Lewis lung cancer. "There is no universal chemotherapeutic agent — they are dependent on the cancer," he observed. "We need to find the right combination of drugs that will work for a given tumour." Eighty per cent of mice treated with nanocells survived beyond 65 days compared with 30 days in the case of mice treated with the best current therapy. "The 65-day period wasn't a benchmark," he noted. "When we started this study, we did not expect the animals to survive this long."
br>
'"/>




Related medicine news :

1. Vitamin B12 can help in detecting cancers
2. Want skin cancer? Please have a cigarette
3. New hope for cancer victims – will vaccine cure the deadly bug
4. Clintons new problem - Is the outgoing American president suffering from skin cancer?
5. Are cancer patients being taken for a ride?
6. Breast cancer treatment to be determined by gene test
7. Ductal lavage may detect early breast cancer
8. Beware of the oral patch! It could be cancer!!!
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Lose stomach for Life....Preventive removal of stomach saves the risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... ... January 23, 2017 , ... During the ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s ... all people and by all people shines as a bright beacon of determination ...
(Date:1/24/2017)... ... , ... The National Council of Alcoholism and Drug Dependence ( NCADD ), ... communities to designate the last full week of January as National Drug and Alcohol ... Myths.” As a community, we can advocate for effective treatment, but also especially ...
(Date:1/23/2017)... New York, NY (PRWEB) , ... January 23, 2017 , ... ... firm, announced today that John J. Nelson, a senior accountant at the Firm, will ... behalf of Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... educational institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in ... by Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted ... expected to grow at a CAGR of 6.0% during ... larger share in the global market between the two ... the hospital segment accounted for the highest share in ... peripheral I.V. catheter market is witnessing high growth rate, ...
(Date:1/23/2017)... Calif. , Jan. 23, 2017  HOPE ... exclusive rights to develop and commercialize nuc ... Therapeutics, a Korean pharmaceutical company. ... DNA aptamer against surface nucleolin found on many ... gemcitabine. Unlike ADCs (antibody drug conjugates) or SMDCs ...
(Date:1/23/2017)... Calif. , Jan. 23, 2017  Based ... market, Frost & Sullivan recognizes Ansell, a global ... Frost & Sullivan Company of the Year Award. ... approach, and a wide global footprint have placed ... the hand protection market. The Company,s established product ...
Breaking Medicine Technology: